Royal Philips (NYSE: PHG, AEX: PHIA) has announced its agreement to acquire SpectraWAVE, Inc., a company specializing in Enhanced Vascular Imaging (EVI) for coronary arteries. This acquisition, revealed on December 15, 2025, aims to advance Philips’ capabilities in the field of coronary intravascular imaging and physiological assessments, which are vital for treating coronary artery disease—a condition affecting over 300 million individuals globally.
Based in Bedford, Massachusetts, SpectraWAVE was established in 2017 and currently employs more than 70 professionals. The company’s innovative technologies, including the HyperVue Imaging System and X1-FFR, leverage artificial intelligence (AI) to enhance intravascular imaging and assessments. These advancements will integrate with Philips’ existing portfolio to improve care delivery for patients undergoing percutaneous coronary interventions (PCIs).
Philips’ CEO, Roy Jakobs, emphasized the company’s commitment to image-guided therapy, stating, “Our global leadership in image guided therapy is driven by deep clinical collaboration combined with our latest technology insights across hardware, software, and AI.” He noted that the integration of SpectraWAVE’s technologies will bolster Philips’ offerings in the coronary intervention segment, enabling better patient care.
The significance of intravascular imaging in PCIs is underscored by a growing body of evidence indicating that these technologies improve patient outcomes. According to Bert van Meurs, Chief Business Leader for Image Guided Therapy at Philips, the acquisition represents a crucial step in enhancing their portfolio with AI-powered technologies. “This partnership allows us to integrate and scale HyperVue and X1-FFR into the world’s leading image-guided therapy ecosystem,” he said.
SpectraWAVE’s HyperVue Imaging System stands out as a notable advancement in the field. It combines DeepOCT (next-generation optical coherence tomography) and near-infrared spectroscopy (NIRS) to create detailed images of coronary arteries during PCIs. This system facilitates rapid setup and automated AI image analysis, improving efficiency for clinicians.
In addition, the X1-FFR technology enables non-invasive ischemia assessments, translating routine angiography images into actionable coronary physiology data. This innovative approach complements Philips’ existing OmniWire iFR technology, broadening the toolkit available to clinicians and promoting greater adoption of coronary physiology practices in everyday medical scenarios.
Philips has established itself as a leader in image-guided therapy, with its Azurion platform at the forefront. Launched in 2017, Azurion is utilized in over 80 countries, treating more than 7.6 million patients annually. The platform integrates various interventional tools, enhancing procedural efficiency and improving patient outcomes.
While the financial specifics of the acquisition remain undisclosed, the collaboration between Philips and SpectraWAVE is poised to drive advancements in minimally invasive procedures, ultimately benefiting millions of patients reliant on coronary interventions each year.
This acquisition aligns with Philips’ broader mission to leverage technology and clinical insights for better health outcomes. The integration of SpectraWAVE’s innovations into Philips’ extensive portfolio signifies a strategic move towards enhancing the standard of care in cardiovascular health.
For further inquiries, please contact:
Michael Fuchs, Philips Global External Relations, +31 614 869 261, [email protected]
Dorin Danu, Philips Investor Relations, +31 205 977 055, [email protected]
